Arrow
Arrow
Slider

Please find below the latest news from Premaitha Health. We also share this news across social media networks.

  • 12 October 2018 - Trading Update & Notice of Results +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Trading Update & Notice of Results

    Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the six-month period ended 30 September 2018 (“H1”).

    H1 revenues were approximately £3.9 million, an increase of 45 per cent over the corresponding period last year. The Company has made a strong start to the second

    Read More
  • 04 October 2018 - $1 million collaboration agreement +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    $1 million collaboration agreement
    Partnership to provide genetic testing based on next generation sequencing for oncology

    Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces a new partnership agreement between the Group’s Yourgene Bioscience division (“Yourgene”) and a leading clinical research organisation in Taiwan (the “Partner”), to deliver next generation sequencing (“NGS”) testing in oncology.

    Under the terms of

    Read More
  • 28 September 2018 - Full year results to 31 March 2018 and half-year trading update +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2018 and half-year trading update

    Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year results for the twelve months ended 31 March 2018; and provides an update on trading in the current financial year to date.  

    Financial highlights

    Revenues increased by 100% to £6.15m (2017: £3.08m), including the first

    Read More
  • 28 September 2018 - Proposed fundraise to raise approximately £2.5 million +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

    Read More
  • 20 September 2018 - Senior Commercial Appointment and Anticipated Directorate Change +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Senior Commercial Appointment and Anticipated Directorate Change

    Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Hayden Jeffreys to a senior commercial role within the Group and that he will be appointed to the Board as Group Commercial Director upon completion of the customary directorate appointment due diligence.

    Hayden has over 20

    Read More
  • 19 September 2018 - Legal Settlement and Licence Agreement with Illumina +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Legal Settlement and Licence Agreement with Illumina

    Manchester, UK – 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading  international molecular diagnostics group, is pleased to announce that the Group has entered into a legal settlement and a licence and supply partnership agreement with Illumina Inc. (“Illumina”) (the “Agreements”), resolving the current non-invasive prenatal testing (“NIPT”) patent infringement litigation.  

    Key Terms of the Agreements

    • Premaitha

    Read More
  • 4 July 2018 - Board Changes +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Board Changes

    Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr Keng Hsu as Chief Operating Officer (Asia).  Dr Stephen Little, currently Chief Executive Officer, will move to the role of Executive Vice Chairman of the Group.

    Alan Chang, Non-executive Director, will step down

    Read More
  • 26 June 2018 - Collaboration with Abnova +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Collaboration with Abnova

    Partnership to develop next generation sequencing capability for single cell analysis

    Manchester, UK – 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has entered into a partnership with Abnova, the world’s largest monoclonal antibody manufacturer, to collaborate on the development of next generation sequencing (“NGS”) capabilities for single cell analysis.

    Abnova has successfully developed a large

    Read More
  • 13 June 2018 - Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award

    Manchester, UK – 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it has today been presented with the “Outstanding Non-invasive Prenatal Screening (NIPS) Solution Provider of the Year” award at the China & America Precision Medicine Forum in Shanghai.  

    The award recognises Premaitha’s excellence as a leading

    Read More
  • 11 June 2018 - Partnership agreement for DNA sequencing technology development +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Partnership agreement for DNA sequencing technology development

    Manchester, UK – 11 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has signed an agreement with Coastal Genomics, a biotechnology engineering firm based in Vancouver, Canada, to develop advanced technologies for clinical DNA sequencing tests.

    Coastal Genomics develops and markets automated solutions to address sample preparation needs across the medical diagnostics sector.

    Read More
  • 5 June 2018 - Premaitha signs NIPT partnership agreement in India +

    Premaitha Health plc
    (“Premaitha”, the “Company” or the “Group”)

    Premaitha signs NIPT partnership agreement in India

    Manchester, UK – 5 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces a 3-year agreement with one of the most advanced clinical laboratory groups in India (“Partner”), to provide a bespoke, high quality and scalable NIPT solution in the Indian market.

    Premaitha, through its Yourgene subsidiary (“Yourgene”),

    Read More
  • 15 May 2018 - Premaitha expands footprint with new laboratories in Kenya and India +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha expands footprint with new laboratories in Kenya and India

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has further extended its customer base, adding two new laboratory hubs, one in Kenya – a new territory for Premaitha – and the other in India.

    In Kenya, the Group has signed

    Read More
  • 15 May 2018 - Year-end Trading Update and £2.5m Fundraising +

    Premaitha Health plc

    (“Premaitha”, the “Company” or the “Group”)

    Year-end Trading Update and £2.5m Fundraising

    Revenues doubled in the year ended 31 March 2018 & An additional £2.5m funds raised

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, provides a trading update for its financial year ended 31 March 2018; announces completion of a share subscription for £2.5m cash at a price of 4.5 pence per

    Read More
  • 29 March 2018 - Premaitha to attend key industry conferences in Asia Pacific +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha to attend key industry conferences in Asia Pacific

    Manchester, UK – 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, is pleased to announce it will be participating in key industry conferences in the Asia Pacific (“APAC”) region to raise awareness of its non-invasive prenatal testing (“NIPT”) solutions.

    Med Lab Asia Pacific

    Med Lab Asia Pacific will be

    Read More
  • 26 March 2018 - Update on UK patent infringement claim received in September 2017 +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Update on UK patent infringement claim received in September 2017

    Manchester, UK – 26 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular
    diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides an update on the first
    stage of its UK defence against the new patent infringement claim, announced on 7 September 2017
    (“New UK Claim”).

    The New UK Claim from Illumina and Sequenom (the “Claimants”)

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen